MAXCYTE INC (MXCT)
US57777K1060 - Common Stock
Taking everything into account, MXCT scores 3 out of 10 in our fundamental rating. MXCT was compared to 58 industry peers in the Life Sciences Tools & Services industry. MXCT has a great financial health rating, but its profitability evaluates not so good. MXCT is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MXCT has reported negative net income.
In the past year MXCT has reported a negative cash flow from operations.
In the past 5 years MXCT always reported negative net income.
MXCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MXCT's Return On Assets of -14.13% is on the low side compared to the rest of the industry. MXCT is outperformed by 60.34% of its industry peers.
Looking at the Return On Equity, with a value of -16.33%, MXCT is in line with its industry, outperforming 48.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.13% | ||
| ROE | -16.33% | ||
| ROIC | N/A |
ROA(3y)-9.69%
ROA(5y)-18.98%
ROE(3y)-10.96%
ROE(5y)-32.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MXCT has a Gross Margin of 88.54%. This is amongst the best in the industry. MXCT outperforms 98.28% of its industry peers.
In the last couple of years the Gross Margin of MXCT has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for MXCT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.34%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
MXCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
MXCT has more shares outstanding than it did 1 year ago.
MXCT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MXCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MXCT has an Altman-Z score of 7.74. This indicates that MXCT is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 7.74, MXCT belongs to the best of the industry, outperforming 87.93% of the companies in the same industry.
There is no outstanding debt for MXCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.74 |
ROIC/WACCN/A
WACC12.03%
2.3 Liquidity
MXCT has a Current Ratio of 10.65. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.65, MXCT belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
MXCT has a Quick Ratio of 9.97. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.97, MXCT belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.65 | ||
| Quick Ratio | 9.97 |
3. Growth
3.1 Past
The earnings per share for MXCT have decreased strongly by -60.87% in the last year.
Looking at the last year, MXCT shows a decrease in Revenue. The Revenue has decreased by -6.72% in the last year.
The Revenue has been growing by 19.89% on average over the past years. This is quite good.
EPS 1Y (TTM)-60.87%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)-6.72%
Revenue growth 3Y16.41%
Revenue growth 5Y19.89%
Revenue growth Q2Q26.12%
3.2 Future
MXCT is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.31% yearly.
MXCT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.84% yearly.
EPS Next Y-37.05%
EPS Next 2Y-7.24%
EPS Next 3Y-3.31%
EPS Next 5YN/A
Revenue Next Year-13.94%
Revenue Next 2Y6.99%
Revenue Next 3Y18.34%
Revenue Next 5Y28.84%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MXCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MXCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MXCT's earnings are expected to decrease with -3.31% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.24%
EPS Next 3Y-3.31%
5. Dividend
5.1 Amount
No dividends for MXCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MAXCYTE INC
NASDAQ:MXCT (5/16/2024, 7:06:19 PM)
After market: 4.8 0 (0%)4.8
+0.03 (+0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap501.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.13% | ||
| ROE | -16.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.54% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.65 | ||
| Quick Ratio | 9.97 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-60.87%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-37.05%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-6.72%
Revenue growth 3Y16.41%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y